Magellan Health (MGLN) 8-K/A Financial Statements and Exhibits

Exhibit 99.1

Unaudited Pro Forma Condensed Consolidated Financial Information

On December 31, 2020, Magellan Health, Inc. (the “Company”) completed the sale of its Magellan Complete Care business (the “MCC Business”) to Molina Healthcare, Inc. (“Molina”), pursuant to a Stock and Asset Purchase Agreement, dated as of April 30, 2020, by and between the Company and Molina, for cash in the amount of $850 million plus closing adjustments of $158 million (subject to post-closing adjustments, if any), and the assumption by Molina of liabilities of the MCC Business.

The sale of the MCC Business is considered a significant disposition for purposes of Item 2.01 of Form 8-K. As a result, the Company prepared the accompanying unaudited pro forma condensed consolidated financial information in accordance with Article 11 of Regulation S-X.

The Company reported its operations of the MCC Business as discontinued operations in its consolidated financial statements included in Form 10-Q for the quarter and year-to-date periods ended June 30, 2020 and September 30, 2020. The accompanying unaudited pro forma condensed consolidated statements of operations for the nine months ended September 30, 2020 and for the years ended December 31, 2019, 2018 and 2017 give effect to the divestiture as if it had occurred on January 1, 2017. The accompanying unaudited pro forma condensed consolidated balance sheet gives effect to this divestiture as if it had occurred on September 30, 2020, the date of the Company’s most recently filed balance sheet.

The unaudited condensed consolidated pro forma financial information should be read in conjunction with (i) the audited consolidated financial statements and accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020, and (ii) the unaudited consolidated financial statements and accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Form 10-Q for the three and nine months ended September 30, 2020 filed with the SEC on October 29, 2020.

The unaudited pro forma condensed consolidated financial information is presented based on assumptions, adjustments, and currently available information described in the accompanying notes and is intended for informational purposes only. The unaudited pro forma condensed consolidated financial information is not necessarily indicative of what the Company’s results of operations or financial condition would have been had the divestiture been completed on the dates assumed. In addition, it is not necessarily indicative of the Company’s future results of operations or financial condition.

MAGELLAN HEALTH, INC. AND SUBSIDIARIES
PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
SEPTEMBER 30, 2020
(Unaudited)
(In thousands)

	Company		Pro Forma			Company
	As Reported		Adjustments			Pro Forma
ASSETS
Current Assets:
Cash and cash equivalents	$	152,050	$	1,013,029	(a)	$	1,165,079
Accounts receivable, net		769,159		-			769,159
Short-term investments		92,686		-			92,686
Pharmaceutical inventory		37,637		-			37,637
Other current assets		95,666		-			95,666
Current portion of assets held for sale		1,144,032		(1,144,032)	(b)		-
Total Current Assets		2,291,230		(131,003)			2,160,227
Property and equipment, net		131,869		-			131,869
Long-term investments		5,623		-			5,623
Deferred income taxes		25,823		(25,823)	(c)		-
Other long-term assets		67,692		-			67,692
Goodwill		806,421		-			806,421
Other intangible assets, net		52,362		-			52,362
Total Assets	$	3,381,020	$	(156,826)		$	3,224,194
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable	$	122,020	$	-		$	122,020
Accrued liabilities		235,152		66,290	(d)		301,442
Medical claims payable		119,922		-			119,922
Other medical liabilities		123,205		-			123,205
Current debt, finance lease and deferred financing obligations		4,308		-			4,308
Current portion of liabilities held for sale		496,272		(496,272)	(b)		-
Total Current Liabilities		1,100,879		(429,982)			670,897
Long-term debt, finance lease and deferred financing obligations		637,093		-			637,093
Deferred income taxes		-		12,777	(c)		12,777
Tax contingencies		11,724		-			11,724
Deferred credits and other long-term liabilities		52,172		5,647	(c)		57,819
Total Liabilities		1,801,868		(411,558)			1,390,310
Stockholders’ Equity:
Ordinary common stock		553		-			553
Additional paid-in capital		1,455,009		-			1,455,009
Retained earnings		1,588,196		254,732	(b)		1,842,928
Accumulated other comprehensive income		121		-			121
Ordinary common stock in treasury, at cost		(1,464,727)		-			(1,464,727)
Total Stockholders’ Equity		1,579,152		254,732			1,833,884
Total Liabilities and Stockholders’ Equity	$	3,381,020	$	(156,826)		$	3,224,194

See notes to pro forma condensed consolidated financial statements.

MAGELLAN HEALTH, INC. AND SUBSIDIARIES
PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF INCOME
YEAR ENDED DECEMBER 31, 2017
(Unaudited)
(In thousands, except per share amounts)

	Company		Pro Forma		Company
	As Reported		Adjustments (e)		Pro Forma
Net revenue:
Managed care and other	$	3,479,182	$	(1,104,425)	$	2,374,757
PBM		2,359,401		115,724		2,475,125
Total net revenue		5,838,583		(988,701)		4,849,882
Costs and expenses:
Cost of care		2,413,770		(859,213)		1,554,557
Cost of goods sold		2,211,910		115,238		2,327,148
Direct service costs and other operating expenses		941,883		(166,595)		775,288
Depreciation and amortization		115,706		(6,820)		108,886
Interest expense		25,977		-		25,977
Interest and other income		(5,887)		2,945		(2,942)
Total costs and expenses		5,703,359		(914,445)		4,788,914
Income (loss) from continuing operations before income taxes		135,224		(74,256)		60,968
Provision (benefit) for income taxes		25,083		(5,453)		19,630
Net income		110,141		(68,803)		41,338
Less: net loss from non-controlling interest		(66)		66		-
Net Income	$	110,207	$	(68,737)	$	41,338
Weighted average number of common shares outstanding — basic		23,333
Weighted average number of common shares outstanding — diluted		24,440
Net income (loss) per common share — basic	$	4.72	$	(2.95)	$	1.77
Net income (loss) per common share — diluted	$	4.51	$	(2.81)	$	1.70

MAGELLAN HEALTH, INC. AND SUBSIDIARIES
PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF INCOME
YEAR ENDED DECEMBER 31, 2018
(Unaudited)
(In thousands, except per share amounts)

	Company		Pro Forma		Company
	As Reported		Adjustments (e)		Pro Forma
Net revenue:
Managed care and other	$	4,878,442	$	(2,527,866)	$	2,350,576
PBM		2,435,709		171,237		2,606,946
Total net revenue		7,314,151		(2,356,629)		4,957,522
Costs and expenses:
Cost of care		3,762,412		(2,207,721)		1,554,691
Cost of goods sold		2,283,022		169,681		2,452,703
Direct service costs and other operating expenses		1,071,535		(297,620)		773,915
Depreciation and amortization		132,660		(20,376)		112,284
Interest expense		35,396		(216)		35,180
Interest and other income		(14,068)		9,184		(4,884)
Total costs and expenses		7,270,957		(2,347,068)		4,923,889
Income (loss) from continuing operations before income taxes		43,194		(9,561)		33,633
Provision (benefit) for income taxes		19,013		(7,556)		11,457
Net Income	$	24,181	$	(2,005)	$	22,176
Weighted average number of common shares outstanding — basic		24,349
Weighted average number of common shares outstanding — diluted		25,035
Net income (loss) per common share — basic	$	0.99	$	(0.08)	$	0.91
Net income (loss) per common share — diluted	$	0.97	$	(0.08)	$	0.89

MAGELLAN HEALTH, INC. AND SUBSIDIARIES
PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF INCOME
YEAR ENDED DECEMBER 31, 2019
(Unaudited)
(In thousands, except per share amounts)

	Company		Pro Forma		Company
	As Reported		Adjustments (e)		Pro Forma
Net revenue:
Managed care and other	$	5,103,393	$	(2,756,458)	$	2,346,935
PBM		2,056,030		162,648		2,218,678
Total net revenue		7,159,423		(2,593,810)		4,565,613
Costs and expenses:
Cost of care		3,940,531		(2,397,007)		1,543,524
Cost of goods sold		1,898,871		160,414		2,059,285
Direct service costs and other operating expenses		1,090,731		(289,064)		801,667
Depreciation and amortization		131,509		(21,142)		110,367
Interest expense		36,153		(285)		35,868
Interest and other income		(19,189)		12,332		(6,857)
Total costs and expenses		7,078,606		(2,534,752)		4,543,854
Income (loss) from continuing operations before income taxes		80,817		(59,058)		21,759
Provision (benefit) for income taxes		24,915		(15,753)		9,162
Net Income	$	55,902	$	(43,305)	$	12,597
Weighted average number of common shares outstanding — basic		24,243
Weighted average number of common shares outstanding — diluted		24,563
Net income (loss) per common share — basic	$	2.30	$	(1.79)	$	0.51
Net income (loss) per common share — diluted	$	2.27	$	(1.76)	$	0.51

MAGELLAN HEALTH, INC. AND SUBSIDIARIES
PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF INCOME
NINE MONTHS ENDED SEPTEMBER 30, 2020
(Unaudited)
(In thousands, except per share amounts)

	Company		Pro Forma		Company
	As Reported		Adjustments (f)		Pro Forma
Net revenue:
Managed care and other	$	1,670,567	$	-	$	1,670,567
PBM		1,722,004		-		1,722,004
Total net revenue		3,392,571		-		3,392,571
Costs and expenses:
Cost of care		1,035,377		-		1,035,377
Cost of goods sold		1,621,577		-		1,621,577
Direct service costs and other operating expenses		620,767		-		620,767
Depreciation and amortization		71,976		-		71,976
Interest expense		24,239		-		24,239
Interest and other income		(2,119)		-		(2,119)
Special charges		24,908		-		24,908
Total costs and expenses		3,396,725		-		3,396,725
Income (loss) from continuing operations before income taxes		(4,154)		-		(4,154)
Provision (benefit) for income taxes		(32,896)		-		(32,896)
Net income from continuing operations		28,742		-		28,742
Income from discontinued operations, net of tax		84,660		(84,660)		-
Net Income	$	113,402	$	(84,660)	$	28,742
Weighted average number of common shares outstanding — basic		25,078
Weighted average number of common shares outstanding — diluted		25,317
Net income (loss) per common share — basic
Continuing operations	$	1.15	$	-	$	1.15
Discontinued operations		3.37		(3.37)		-
Consolidated operations	$	4.52	$	(3.37)	$	1.15
Net income (loss) per common share — diluted
Continuing operations	$	1.14	$	-	$	1.14
Discontinued operations		3.34		(3.34)		-
Consolidated operations	$	4.48	$	(3.34)	$	1.14

MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION
NINE MONTHS ENDED SEPTEMBER 30, 2020

(a) - Adjustment reflects the net cash proceeds from the sale of the Magellan Complete Care ("MCC") reporting unit as if the closing date were September 30, 2020.

(b) - Adjustment reflects the assets and liabilities of the MCC reporting unit, which were previously classified as held for sale and impact to the related equity.

(c) - Adjustment reflects the tax impact to deferred taxes upon the close of the transaction.

(d) - Adjustment reflects liabilities for income taxes payable and other liabilities generated by the transaction.

(e) - Adjustments reflect the historical operating results of the MCC reporting unit and the impact of intercompany revenue, cost of goods sold and direct service costs previously eliminated on a consolidated basis.

(f) - Adjustment reflects the operating results of the MCC reporting unit reported as discontinued operations.